Citigroup
ARLZ

Citigroup’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Citigroup’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-900
Closed – – 8051
2018
Q2 		$0 Hold
900
– – ﹤0.01% 7937
2018
Q1 		$1K Hold
900
– – ﹤0.01% 7509
2017
Q4 		$1K Sell
900
-2,850
-76% -$4.68K ﹤0.01% 7528
2017
Q3 		$9K Buy
3,750
+123
+3% +$165 ﹤0.01% 6736
2017
Q2 		$5K Sell
3,627
-1,376
-28% -$1.99K ﹤0.01% 6778
2017
Q1 		$11K Sell
5,003
-58
-1% -$218 ﹤0.01% 6546
2016
Q4 		$22K Buy
5,061
+4,161
+462% +$19.8K ﹤0.01% 6502
2016
Q3 		$4K Sell
900
-900
-50% -$4.1K ﹤0.01% 6857
2016
Q2 		$6K Sell
1,800
-43,874
-96% -$166K ﹤0.01% 6753
2016
Q1 		$162K Buy
+45,674
New +$235K ﹤0.01% 5285

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citigroup's ARLZ Position: Q3 2018 in Review

Citigroup sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 900 shares.

Citigroup first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $162K in Q1 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • Citigroup reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • Citigroup sold 900 Aralez Pharmaceuticals Inc. shares in Q3 2018.
  • Citigroup first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
  • Citigroup's Aralez Pharmaceuticals Inc. position peaked at $162K in Q1 2016.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Citigroup's 13F filing for Q3 2018, filed 13 Nov 2018.